338 related articles for article (PubMed ID: 11165117)
1. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
[TBL] [Abstract][Full Text] [Related]
3. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.
Spanu T; Luzzaro F; Perilli M; Amicosante G; Toniolo A; Fadda G;
Antimicrob Agents Chemother; 2002 Jan; 46(1):196-202. PubMed ID: 11751134
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
Khan MK; Thukral SS; Gaind R
Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
[TBL] [Abstract][Full Text] [Related]
5. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.
Tsai HY; Chen YH; Tang HJ; Huang CC; Liao CH; Chu FY; Chuang YC; Sheng WH; Ko WC; Hsueh PR
Diagn Microbiol Infect Dis; 2014 Nov; 80(3):222-6. PubMed ID: 25139843
[TBL] [Abstract][Full Text] [Related]
6. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
[TBL] [Abstract][Full Text] [Related]
7. [Enzymatic resistance to beta lactam antibiotics within the genus Proteus and evaluation of Proteus mirabilis phenotypes and genotypes for resistance to third- and fourth-generation cephalosporins].
Rodríguez C; Radice M; Perazzi B; Castro S; Juárez J; Santini P; Vay C; Famiglietti A; Gutkind G
Enferm Infecc Microbiol Clin; 2005 Mar; 23(3):122-6. PubMed ID: 15757582
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
Livermore DM; Yuan M
J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
[TBL] [Abstract][Full Text] [Related]
9. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
[TBL] [Abstract][Full Text] [Related]
11. Molecular Characterization of β-Lactam Resistance and Antimicrobial Susceptibility to Possible Therapeutic Options of AmpC-Producing Multidrug-Resistant
Rubic Z; Soprek S; Jelic M; Novak A; Goic-Barisic I; Radic M; Tambic-Andrasevic A; Tonkic M
Microb Drug Resist; 2021 Feb; 27(2):162-169. PubMed ID: 32429775
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
Gatermann S; Marre R
Infection; 1991; 19(2):106-9. PubMed ID: 1646771
[TBL] [Abstract][Full Text] [Related]
13. IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.
Dixon N; Fowler RC; Yoshizumi A; Horiyama T; Ishii Y; Harrison L; Geyer CN; Moland ES; Thomson K; Hanson ND
Antimicrob Agents Chemother; 2016 Oct; 60(10):6418-21. PubMed ID: 27503648
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
15. [Characteristic of resistance to beta-lactam antibiotics of nosocomial strains of Proteus mirabilis].
Ivanov DV
Zh Mikrobiol Epidemiol Immunobiol; 2008; (6):75-8. PubMed ID: 19189465
[TBL] [Abstract][Full Text] [Related]
16. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
17. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
[TBL] [Abstract][Full Text] [Related]
18. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the in vitro activity of piperacillin/tazobactam.
Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
[TBL] [Abstract][Full Text] [Related]
20. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]